---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-25-015955"
form_type: "8-K"
ticker: "URGN"
cik: "0001668243"
company_name: "UroGen Pharma Ltd."
filed_at: "2025-05-12T23:59:59+00:00"
generated_at: "2026-05-21T23:49:58.916635+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# UroGen Pharma Q1 2025: JELMYTO revenue $20.3M, net loss widens to $43.8M; UGN-102 PDUFA June 13

## Summary
- JELMYTO net sales $20.3M (+8% YoY); underlying demand grew 12%.
- Net loss of $43.8M ($0.92 per share) vs $32.3M ($0.87) in Q1 2024.
- Cash and marketable securities $200.4M; FY2025 JELMYTO revenue guidance unchanged at $94–$98M.
- UGN-102 NDA under FDA review; PDUFA target action date June 13, 2025; ODAC meeting May 21.
- UGN-501 acquisition from IconOVir expensed; UGN-103 Phase 3 UTOPIA trial enrollment to complete mid-2025.

## SEC filing metadata
- accession: 0001437749-25-015955
- form_type: 8-K
- ticker: URGN
- cik: 0001668243
- company_name: UroGen Pharma Ltd.
- filed_at: 2025-05-12T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1668243/000143774925015955/0001437749-25-015955-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1668243/000143774925015955/urgn20250428_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-25-015955
- JSON: https://secwatch.observer/filing/0001437749-25-015955.json
- Plain text: https://secwatch.observer/filing/0001437749-25-015955.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.